<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865668</url>
  </required_header>
  <id_info>
    <org_study_id>CR108198</org_study_id>
    <secondary_id>28431754DIA1073</secondary_id>
    <nct_id>NCT02865668</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (50 mg/500 mg) With Respect to the Metformin XR Tablet (Locally Sourced From Canada [GLUMETZA, 1 x 500 mg]) Coadministered With Canagliflozin (1 x 50 mg) in Healthy Fed and Fasted Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate bioequivalence of the metformin component of the
      Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablet
      coadministered with canagliflozin in healthy fed and fasted participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Metformin</measure>
    <time_frame>Predose, 0.5 hour (hr), 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, hr postdose on Day 1; 24 hr postdose on Day 2</time_frame>
    <description>The Cmax is the maximum observed plasma concentration of metformin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time 0 to The Time of the Last Observed Quantifiable Concentration (AUClast) of Metformin</measure>
    <time_frame>Pre-dose, 0.5 hour (hr), 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, hr post dose on Day 1; 24 hr post-dose on Day 2</time_frame>
    <description>The AUClast is the area under the plasma concentration time curve from time 0 to the time of the last observed quantifiable concentration (Clast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time 0 to Infinite Time [AUC (0-infinity)] of Metformin</measure>
    <time_frame>Pre-dose, 0.5 hour (hr), 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, hr post dose on Day 1; 24 hr post-dose on Day 2</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Screening to End of study (up to 58 Days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with one Extended Release (XR) tablet of metformin of 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with one metformin (XR) tablets of 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]</intervention_name>
    <description>Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.</description>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <description>Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.</description>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Extended Release (XR)</intervention_name>
    <description>Participants will receive 1 metformin XR tablet of 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.</description>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Contraceptive use by men or women should be consistent with local regulations
             regarding the use of contraceptive methods for participant participating in clinical
             studies

          -  Before randomization, a woman must be either Not of childbearing potential or of
             childbearing potential and agrees to use a highly effective method of contraception
             (failure rate of less than [&lt;]1 percent [%] per year when used consistently and
             correctly) throughout the study

          -  All women must have a negative urine pregnancy test at Screening and on Day -1 of each
             Treatment Period

          -  Body mass index (BMI) (weight [kg]/height^2 [m]2) between 18 and 30 kg/m^2
             (inclusive), and body weight not less than 50 kilogram (kg)

          -  Blood pressure between 90 and 140 millimeter of mercury (mmHg), inclusive, systolic
             and no higher than 90 mmHg diastolic at Screening or Day -1 of each Treatment Period

          -  Normal renal function evidenced by estimated glomerular filtration rate (eGFR) &gt;=90
             milliliters per minute (mL/min)/1.73m2 using the Modification of Diet in Renal Disease
             Study (MDRD) equation as defined in the protocol

        Exclusion Criteria:

          -  History of or current clinically significant medical illness including (but not
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,
             coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid
             abnormalities, significant pulmonary disease, including bronchospastic respiratory
             disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease,
             neurologic or psychiatric disease, infection, or any other illness that the
             investigator considers should exclude the participant or that could interfere with the
             interpretation of the study results

          -  Clinically significant abnormal values for hematology, clinical chemistry, or
             urinalysis as assessed by the investigator at Screening or Day -1 of the first
             Treatment Period

          -  Clinically significant abnormal physical examination, vital signs, or 12 lead
             electrocardiogram (ECG) (Screening only) as assessed by the investigator at Screening
             or on Day -1 of the first Treatment Period as deemed appropriate by the investigator

          -  Use of any prescription or nonprescription medication (including vitamins and herbal
             supplements), except for acetaminophen, hormonal contraceptives and hormonal
             replacement therapy within 14 days before the first dose of the study drug is
             scheduled

          -  History of, or a reason to believe a participant has a history of drug or alcohol
             abuse within the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

